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REVIEWS AND COMMENTARY • STATE OF THE ART
Breast MRI is an indispensable modality, along with mammography and US. Its main indications are stag-
ing of known cancer, screening for breast cancer in women 
at increased risk, and evaluation of response to neoadju-
vant chemotherapy (1–3). As opposed to mammography 
and US, MRI is a functional technique. Heywang et al 
(4) and Kaiser and Zeitler (5) independently introduced 
this technique in the 1980s. Contrast material–enhanced 
MRI evaluates the permeability of blood vessels by using 
an intravenous contrast agent (gadolinium chelate) that 
shortens the local T1 time, leading to a higher signal on 
T1-weighted images (6). The underlying principle is that 
neoangiogenesis leads to formation of leaky vessels that 
allow for faster extravasation of contrast agents (7), thus 
leading to rapid local enhancement. Despite improve-
ments in the technique of breast MRI, this principle is 
still the basis of all clinical MRI protocols. However, most 
MRI protocols nowadays are multiparametric (8,9). This 
review describes the current state of the art in breast MRI, 
with a focus on the major indications and the potential 
indication-based adaptations to the imaging protocol to 
maximize its value.
Requirements for Breast MRI
Breast MRI studies should be interpreted by radiologists 
with expertise in breast imaging, including mammographic 
and US studies, as these examinations are often comple-
mentary. Although empirical data on the learning curve for 
breast MRI are lacking, some studies showed improved per-
formance of radiologists over time (10), and reporting breast 
MRI studies requires sufficient exposure to the technique.
It is best practice to use a field strength of at least 1.5 
T to acquire images at a sufficiently high spatial resolution 
(1–3). Utilization of a dedicated breast coil is mandatory 
to obtain images of diagnostic quality. Women lie in the 
prone position with the breasts hanging free in the recesses 
of the coil. This design allows the breast tissue to spread, 
which facilitates detection of abnormalities and prevents 
motion artifacts induced by respiration (11,12). A breast 
coil should have at least four channels, but modern designs 
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pression. Images are usually acquired in the axial plane, which 
is faster than sagittal acquisition and provides a better overview 
of both breasts. A native T1-weighted acquisition should be 
obtained prior to contrast material administration. Contrast 
material should be administered at a maximum dose of 0.1 
mmol per kilogram of body weight, as there is no evidence for 
better performance with higher doses (18,19). Preferentially, a 
power injector should be used at a flow rate of 2 mL/sec. The 
contrast material bolus should be flushed with saline (a bolus 
of approximately 20 mL).
After contrast material administration, the T1-weighted 
acquisition is repeated to depict enhancing abnormalities. It 
is essential to obtain an image approximately 60–90 seconds 
after contrast material administration, as most breast cancers 
will show peak enhancement at that time. Lesion detection is 
primarily performed by using these postcontrast images. For 
images obtained without fat suppression, creating subtraction 
images from the pre- and postcontrast acquisitions is required 
(20). Subtraction images are also helpful for acquisitions with 
fat suppression because they help differentiate truly enhanc-
ing structures from lesions with native high signal intensity 
at T1 (21). Generating maximum intensity projections from 
these subtracted images aids in rapid lesion detection (22,23). 
However, motion artifacts, chemical shift artifacts, and poor 
fat suppression may obscure small lesions on maximum in-
tensity projection images.
By convention, breast MRI should depict all enhancing can-
cers 5 mm or larger in size. Therefore, the section thickness of 
T1-weighted acquisitions should be no more than 2.5 mm. Be-
cause morphologic evaluation requires much finer detail, the in-
plane pixel size should be 1 3 1 mm or lower (1–3). By using 
modern MRI units and breast coils, much higher resolutions (1 
mm isotropic and lower) are easily obtainable without lengthen-
ing the acquisition time per volume beyond 90 seconds. This 
allows for reconstruction in any plane, facilitating evaluation of 
lesions, especially the distribution of non-mass lesions.
For lesion detection, the acquisition of two T1-weighted ac-
quisitions at the specified time points (one before and one ap-
proximately 90 seconds after contrast material administration) is 
usually sufficient, as can be inferred from the success of abbrevi-
ated protocols for breast MRI (24). All other sequences improve 
the differentiation of breast lesions, with the aim to prevent false-
positive and false-negative classification.
Dynamic Evaluation with Time–Signal Intensity 
Curves
Dynamic analysis investigates the permeability of the vessels 
that supply a lesion (5). This is done by obtaining a series of T1-
weighted acquisition between 5 and 7 minutes after contrast 
material administration (25,26). In the case of leaky vessels, the 
peak contrast material accumulation will have passed, and con-
trast material is being removed from the lesion. In lesions with 
less-permeable vessels, the contrast gradient over the vessel wall 
will still be positive, and therefore the enhancement of the le-
sion still increases. This is reflected in the shape of the time–
signal intensity curves; a persistent increase is most commonly 
seen in benign lesions, whereas a decrease in the late phase is 
Abbreviations
ADC = apparent diffusion coefficient, BCS = breast-conserving surgery, 
BI-RADS = Breast Imaging Reporting and Data System, DCIS = ductal 
carcinoma in situ, DWI = diffusion-weighted imaging, EPI = echo-pla-
nar imaging, HER2 = human epidermal growth factor receptor 2, NAC 
= neoadjuvant chemotherapy, NME = non-mass enhancement, pCR = 
pathologic complete response, SNR = signal-to-noise ratio
Summary
Indications for breast MRI are consolidating; MRI for screening 
leads to earlier cancer detection in virtually all evaluated populations; 
in the hands of experienced teams, MRI allows for improvement of 
surgical practice, reducing the number of re-excisions while prevent-
ing unnecessary mastectomies; and MRI allows for patient selection 
for neoadjuvant chemotherapy and is the technique of choice to 
support modification of therapeutic agents and for presurgical assess-
ment of residual tumor size to determine breast conservation surgery 
candidacy.
Essentials
 n Breast MRI is a key imaging technique for breast imaging.
 n Multiparametric breast MRI protocols can be adapted to the clini-
cal indication.
 n Translating preoperative MRI for extent of disease evaluation to 
better surgical outcomes requires experience in incorporating MRI 
findings for MRI-guided surgery, with lesion localization where 
appropriate.
 n Screening with breast MRI leads to earlier cancer detection in all 
women.
 n In the neoadjuvant setting, enhancement characteristics of lesions 
change, and assessment should be adapted to the clinical question 
that is to be answered.
have 16 channels or more, and sometimes also dedicated chan-
nels for the axillary region (13,14). In general, coils with more 
channels obtain a higher signal-to-noise ratio (SNR). More 
channels also enable the use of higher parallel imaging factors, 
which can increase the speed of image acquisition (13–15).
Because breast MRI aims to depict lesions that are 
occult with other modalities, it is essential that imaging facili-
ties have tools to biopsy and localize these lesions for surgery 
(16,17). This may require an additional biopsy coil, as the lat-
est generations of breast coils have closed recesses because of the 
high number of channels that are brought in proximity to the 
breast, consequently blocking access to the breast for interven-
tional procedures. Also, a device that immobilizes the breast dur-
ing biopsy is indispensable because introduction of a needle will 
change the shape of the breast and the position of the lesion.
Components of the Multiparametric Breast 
MRI Protocol
Breast MRI has evolved from a primarily contrast-enhanced tech-
nique to a multiparametric technique, in which T2-weighted 
and diffusion-weighted imaging (DWI) are routinely per-
formed. Still, the basis for any MRI protocol is a dynamic T1-
weighted contrast-enhanced sequence.
T1-weighted Imaging
For the T1-weighted series, intravenous access is required. T1-
weighted imaging may be performed with or without fat sup-
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common in malignant lesions (27). To improve lesion classifica-
tion, the most suspicious curve observed (washout . plateau . 
persistent) within a small region of interest (ROI) (typically 
3 3 3 3 1 voxels) in the lesion is used. Approximately 85% 
of cancers manifest with a washout curve (26–29). Persistent 
curves are rare in malignancies, although they may be present 
in ductal carcinoma in situ (DCIS) and more diffuse-growing 
invasive cancers, particularly lobular breast cancers. ROI-based 
measurement of time–signal intensity curves can be replaced 
by soft-copy reading with visual assessment of the enhance-
ment behavior of the entire tumor (ie, scrolling through the 
dynamic series of a given section). Also, software programs are 
available that generate color map overlays of the enhancement 
curve distribution within a lesion, which also replaces drawing 
ROIs and generating time–signal intensity curves.
Ultrafast Breast MRI
Ultrafast breast imaging documents the early inflow of contrast 
material in a lesion (28–30). Malignancies enhance both earlier 
and faster than benign lesions. Consequently, the first lesion that 
enhances in the breast is the most suspicious. Most breast cancers 
start to enhance within 10 seconds after the arrival of contrast 
material in the major vessels, whereas benign lesions, on aver-
age, enhance later (.15 seconds) (31,32). Faster enhancement 
translates to a steeper upslope of the first part of the time–signal 
intensity curve. Lesions can therefore be classified by using the 
time to enhancement relative to that in the descending aorta and 
the maximum slope of the enhancement curve (Fig 1). Accu-
rate determination of these parameters requires very fast imag-
ing techniques, typically on the order of 5 seconds per whole 
breast volume. When used for visual inspection, these volumes 
should still meet the minimum spatial requirements for T1-
weighted images described 
above. This has become 
possible by using view-
sharing and compressed 
sensing techniques at 3.0 
T (33,34) but is not fea-
sible with all clinical MRI 
units. However, ultrafast 
breast imaging enables 
dynamic evaluation of 
lesions without the pen-
alty of a longer acquisi-
tion time and provides a 
similar accuracy for lesion 
classification.
T2-weighted 
Imaging
T2-weighted imaging is 
included in the standard 
MRI protocol (35,36). 
T2-weighted imaging 
with fat suppression en-
ables easy visualization of 
cysts. T2-weighted imag-
Figure 1: Graph shows inflow curves obtained from ultrafast MRI for two breast lesions. The red curve is ob-
tained from an invasive ductal carcinoma manifesting as an irregular mass (arrow) located posteriorly in the right 
breast of a 53-year-old woman (upper inset, axial view). The curve shows early (only 8 seconds after the aorta) 
and rapid (steep slope) enhancement. Note that noise in the acquisition may lead to some fluctuation of the 
signal prior to contrast material administration. The green curve is obtained from a fibroadenoma manifesting as 
a well-circumscribed mass (arrow) located anterior in the right breast of a 46-year-old woman (lower inset, axial 
view). The curve shows late (17 seconds after the aorta) and intermediate enhancement.
ing without fat suppression allows better depiction of lesion mor-
phology. Most masses with high signal intensity at T2-weighted 
imaging are benign (eg, apocrine metaplasia, cyst, myxoid fibroad-
enoma, fat necrosis, and lymph nodes) (36). Most cancers do not 
show high signal intensity relative to parenchyma at T2-weighted 
imaging because of their high cellularity and low water content. 
However, mucinous carcinoma, necrotic cancer, and metaplastic 
carcinoma can have high signal intensity on T2-weighted images 
(2). T2-weighted imaging also allows the depiction of perifocal or 
prepectoral edema within the breast, which improves lesion clas-
sification (lesions with edema are more often malignant) and is a 
poor prognostic sign in patients with known breast cancer (37,38). 
Several studies have reported that T2-weighted imaging increases 
the specificity for differentiation of benign and malignant lesions 
(39,40). However, other investigators have questioned the added 
value of T2-weighted imaging in routine breast MRI, especially 
for inversion-recovery pulse sequences (1).
DWI Sequences
DWI quantifies the random movement of water molecules in 
tissue, which is influenced by tissue microstructure and cell 
density. This is achieved by applying motion-sensitizing gra-
dients (b factors) to an (in essence) T2-weighted echo-planar 
imaging (EPI) sequence (41,42). Cancers show decreased wa-
ter diffusion because of increased cell density, which leads to 
higher signal intensity at DWI. DWI is performed in a short 
acquisition time and does not rely on the administration of a 
contrast agent. To obtain adequate DWI acquisitions, the se-
lection of appropriate b values, adequate fat suppression, mini-
mization of artifacts, and sufficient SNR are crucial (42).
The apparent diffusion coefficient (ADC) is a quantitative 
measure of diffusivity derived from DWI (Appendix E1 [online]). 
Mann et al
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used (45). Consequently, it may be beneficial to perform DWI 
before contrast material administration.
Adequate fat suppression is critical in DWI to minimize EPI-
related artifacts such as ghosting and chemical shift. Also, if fat 
suppression is inadequate, measurement of ADC is underesti-
mated (49). Spectral selection-attenuated inversion recovery, or 
SPAIR, is commonly used (50). Short inversion time inversion 
recovery is more robust but results in a lower SNR and more 
variability in ADC measurements (51).
Single-shot EPI–based readout is the standard sequence for 
DWI acquisition, because it is fast and motion insensitive and 
yields a high SNR (52). However, it is susceptible to artifacts such 
as ghosting, chemical shift, and distortion, which are mainly due 
to the slow traversal through k-space along the phase-encoding 
direction. To reduce these artifacts, readout-segmented EPI has 
been used to restrict the readout acquisition in each shot, leading 
to a reduction of susceptibility artifacts at the expense of longer 
imaging time (52). Several studies have demonstrated the supe-
rior image quality of readout-segmented EPI DWI compared 
with single-shot EPI DWI (53,54), although the SNR is lower.
Alternatively, reduced field of view techniques obtain images 
for a target by reducing matrix size, also leading to decreased sus-
ceptibility artifacts and increased spatial resolution at the expense 
of longer imaging time compared with single-shot EPI DWI. 
A study (55) reported that reduced field of view EPI provided 
higher image quality, lesion conspicuity, and SNR than did read-
out-segmented EPI (Fig 2).
Values are usually expressed in 1023 mm2/sec. Because of the hin-
dered diffusion in cancers, mean ADCs are generally low (range, 
0.8–1.3 3 1023 mm2/sec) compared with those in benign lesions 
(range, 1.2–2.0 3 1023 mm2/sec) (43). Consequently, cancers 
have a low signal intensity on the derived ADC maps.
Studies have reported that diagnostic performance in distin-
guishing benign and malignant lesions is affected neither by the 
choice of field strength (1.5-T or 3.0-T MRI unit [43]) nor by 
the combination of multiple b values (44,45). Although sensitivity 
and specificity were not affected by the combination of b values 
in a meta-analysis of 26 studies, the ADC measurements did vary 
depending on b values (45) because the signal decay is not truly 
monoexponential but in fact decreases at higher b values. Conse-
quently, using lower b values yields higher ADCs, and using higher 
b values yields lower ADCs (42). A study (46) has shown that the 
contrast of tumor to normal parenchyma increases with a b value 
from 0 to 1500 sec/mm2 and decreases with a b value greater than 
1500 sec/mm2, but the higher b values lead to decreased SNR. In 
addition, DWI performed by using a b value of less than 1000 
sec/mm2 showed the greatest accuracy in distinguishing benign 
and malignant lesions (47,48). Considering these studies and to 
ensure reproducibility of ADCs between sites, b values of 0 and 
800 sec/mm2 are recommended for clinical practice, providing 
a balance between sufficient diffusion weighting and acceptable 
SNR. In addition, although contrast material injection before 
DWI does not significantly affect the diagnostic properties of the 
ADC, ADCs may change depending on the exact sequence type 
Figure 2: Axial images from breast MRI in a 52-year-old woman with an invasive ductal carcinoma. (a) Contrast-enhanced T1-weighted image 
shows a round rim-enhancing mass. (b) Image from single-shot echo-planar imaging (EPI) (conventional) diffusion-weighted imaging (DWI) shows 
more artifacts in the background. The shape of the mass is distorted. (c) Apparent diffusion coefficient (ADC) map from conventional DWI shows the 
mass with decreased signal intensity, suggesting diffusion restriction (arrow). (d) Image from read-out segmented EPI (rs-EPI) DWI and (e) ADC map 
of rs-EPI DWI show improved depiction of lesion morphology (conspicuity) (arrow) and fewer artifacts in the background. (f) Image from reduced field 
of view (rFOV) DWI and (g) ADC map of rFOV DWI show improved depiction of morphologic detail and intratumoral heterogeneity (arrow). (Images 
courtesy of Hee Jung Shin, MD, PhD, Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.)
Breast MRI: State of the Art
524 radiology.rsna.org  n Radiology: Volume 292: Number 3—September 2019 
their shape, margins, and internal enhancement pattern. Areas 
of NME are further described according to distribution and in-
ternal enhancement pattern. For both lesion types, initial and 
delayed phase enhancement are described to improve the dif-
ferential diagnosis.
Approximately two-thirds to three-quarters of cancers mani-
fest as a mass, including most invasive ductal cancers (60,61); the 
remainder are visible as areas of NME, including the majority of 
cases of DCIS (60). Typical malignant masses have an irregular 
size and margin, heterogeneous or rim enhancement patterns, 
and show washout (Fig 2). Classic malignant areas of NME have 
a segmental distribution and a clumped or clustered ring pattern 
of internal enhancement (Fig 4). While most cancers are easily 
recognizable by their morphologic features alone, smaller lesions 
are more difficult to assess (62). In general, the features of NME 
are less specific than those of masses (60,63,64). Foci have a like-
lihood of malignancy of 2.9%–6% (65).
On the basis of the above analysis of morphologic and kinetic 
features, the radiologist assigns a final assessment, or BI-RADS 
score, from 0 to 6. However, unlike the Prostate Imaging Re-
porting and Data System, or PI-RADS, lexicon, the BI-RADS 
lexicon does not provide information on the associated “likeli-
hood of malignancy” of the individual findings. It provides de-
scriptor terms—not an interpretation guideline. To aid in the 
classification, a tree flowchart has been developed in which a de-
cision rule assigns the levels of suspicion to specific combinations 
of imaging features. The decision tree may standardize reporting 
and improve the discrimination between benign and malignant 
lesions. It incorporates some of the BI-RADS descriptors as well 
as the presence or absence of a root sign and edema. A root sign 
The Multiparametric Protocol
The various components of the basic multiparametric protocol 
are shown in Figure 3. For further improvement of lesion clas-
sification, other sequence types and postprocessing methods 
are being evaluated. These include the quantitative assessment 
of contrast material enhancement, advanced DWI techniques, 
and spectroscopic imaging. Several techniques are described in 
Appendix E1 (online).
Breast Lesion Evaluation at Breast MRI
Reporting of breast MRI is standardized in the American Col-
lege of Radiology Breast Imaging Reporting and Data System 
(BI-RADS) (56). A standard report contains the clinical indica-
tion, the MRI sequences and postprocessing methods that were 
used, and the amount and type of contrast agent administered. 
Subsequently, the composition of the breast and the amount 
of background parenchymal enhancement (BPE) should be 
stated. For both measures, a higher fraction is associated with 
a higher likelihood of malignancy being present (57,58). Still, 
the correlation between the amount of fibroglandular tissue, 
amount of BPE, and breast cancer risk in the future is incom-
pletely understood. A higher fraction of BPE leads to a higher 
risk of false-positive findings (59).
The morphologic and kinetic features of findings are de-
scribed by using the BI-RADS lexicon. Lesions are categorized 
as foci (,5 mm of enhancement and by definition too small to 
characterize any further, but standing out from the surroundings), 
masses (space-occupying lesions), and non-mass enhancement 
(NME) (areas of enhancement without a clear space-occupying 
lesion present). Masses are further characterized on the basis of 
Figure 3: Components of the basic multiparametric breast MRI protocol. In general, the protocol is begun with the non–contrast-
enhanced acquisitions (T2-weighted and diffusion-weighted imaging [DWI]). This is followed by a native T1-weighted acquisition 
and subsequently the contrast-enhanced series (ultrafast [UF] imaging and regular T1-weighted imaging). For screening purposes, 
this protocol may be abbreviated to contain only the T1-weighted acquisitions before and directly after contrast material admin-
istration, with or without the acquisition of ultrafast images (or only ultrafast images if they are of sufficiently high resolution). For 
lesion discrimination, adding T2-weighted imaging and DWI is beneficial. The information from ultrafast images is in essence 
similar to (although somewhat more discriminative than) the delayed phase dynamics, and these can therefore both be used. After 
neoadjuvant chemotherapy the delayed phase is essential to document the presence of residual ductal carcinoma in situ.
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Women with any of these factors are therefore good candidates 
for preoperative evaluation with MRI. In addition, most guide-
lines recommend MRI for the staging of invasive lobular can-
cers, as the performance of conventional modalities and clinical 
breast examination is limited.
Quality of preoperative staging.—By using breast MRI, 
approximately 75% of cancers are measured within 1 cm 
from the pathologic size, with similar percentages of over- 
and underestimation. However, reported accuracies of tu-
mor size measurement vary widely, ranging from less than 
50% of cancers measured within 1 cm to more than 80% 
of cancers measured within 5 mm. Regardless, most studies 
conclude that size estimations with MRI are more reliable 
than those with clinical examination, mammography, or US. 
Accuracy decreases in larger cancers and is worse in NME 
than in mass lesions (75–77). It is important to realize that 
the pathologic reference standard has substantial limitations. 
For example, the pathologic evaluation of breast specimens 
changes with gross anatomy, and a perfect correlation can 
never be achieved.
The benefit of using MRI to assess tumor size is particularly 
strong for invasive lobular carcinomas (78–80). Likewise, the de-
piction of DCIS components related to invasive cancers is much 
better than that with mammography, the latter missing more 
than half of all lesions, whereas the sensitivity for large DCIS 
components with MRI approaches 100% (81,82). Breast MRI 
is also more accurate in the depiction of pure DCIS lesions, par-
ticularly high-grade lesions (83,84) (Fig 4); however, small DCIS 
lesions detected because of calcifications at mammography may 
be occult at MRI.
Management of lesions detected at MRI.—With preoperative 
MRI, the detection of mammographic occult lesions in the af-
fected breast is common. A meta-analysis of 50 studies (85) found 
that two-thirds of additional findings (67%) are malignant, and 
is a spiculelike extension from the lesion margin, even when the 
rest of the margin is smooth; its presence strongly increases the 
likelihood of malignancy. Study results show the decision tree 
improved the diagnostic accuracy of inexperienced readers and 
reduced the number of benign findings at biopsy by more than 
25% (66,67).
Although findings from ultrafast acquisitions and DWI 
have not been incorporated into the decision tree, many studies 
have shown that the combination of ultrafast acquisitions, T2-
weighted imaging, and DWI improves the diagnostic accuracy 
of discriminating benign from malignant masses. Late and slow 
initial enhancement, high T2 signal, and high ADC substan-
tially decrease the likelihood of malignancy and may be used to 
avoid biopsy. In particular, ADCs greater than 1.4 3 1023 mm2/
sec are exceptionally rare in cancers. On the other hand, early 
and fast enhancement, a low T2 signal, the presence of edema, 
and a low ADC increase the level of suspicion. A specificity of 
90% has been reported with use of a multiparametric approach 
(68). BI-RADS and supplemental descriptors are presented in 
Table 1.
Breast MRI in Clinical Practice
Staging in Women with Known Breast Cancer
Preoperative MRI for local staging of a known breast cancer 
is a common but controversial indication. The detection of 
more disease at MRI has not translated into improved out-
comes. Consequently, guidelines differ widely in their recom-
mendations for the performance of preoperative breast MRI 
in women with a new diagnosis of breast cancer (1–3,69–72) 
(Table 2).
Women with a diagnosis at a young age; those with an initial 
cancer manifesting as interval cancer; those with hormone receptor–
negative cancers or dense breasts; and breast conservation with-
out radiation therapy are all associated with an increased risk 
of invasive interval cancers in the postoperative period (73,74). 
Figure 4: (a) Mediolateral oblique view from a screening mammogram in a 54-year-old woman shows a small cluster of microcalcifications in 
the upper outer quadrant of the right breast. A detailed spot magnification view is given in (b). Stereotactic biopsy revealed grade 2 ductal carci-
noma in situ (DCIS). (c) Maximum intensity projection from subsequent staging MRI shows a large area of segmental clumped non-mass enhance-
ment in the right breast, representing the actual extent of disease.
Breast MRI: State of the Art
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Table 2: Recommendations for Selecting Patients with Known Breast Cancer for Preoperative Evaluation with Breast 
MRI according to Various National and International Guidelines
Guideline Recommendation
EUSOBI (2008) Dense breasts; invasive lobular carcinoma; screening of the contralateral breast (all patients)
EUSOMA (2010) Invasive lobular carcinoma; patients at high risk; patients , 60 years with size discrepancy 
between mammography and US . 1 cm; patients eligible for partial breast irradiation
ACR practice guideline (2018) No subgroups defined; MRI useful for determining extent of tumor, evaluation of the 
tumor’s relation to the deep fascia, and screening of the contralateral breast
NCCN breast cancer guideline (2018) No subgroups defined; MRI is optional
NICE breast cancer guideline (2018) Discrepancy in clinical examination, mammography, and US; dense breasts precluding size as-
sessment at mammography; invasive lobular carcinoma if breast-conserving therapy is planned
Dutch breast cancer guideline (2018) Discrepancy in clinical examination, mammography, and US; invasive lobular carcinoma if 
breast-conserving therapy is planned; high-grade DCIS and uncertain extent; DCIS with 
microinvasion
AGO (German Gynecologic Oncology  
 group) (2018)
MRI optional in dense breasts, nipple involvement, invasive lobular carcinoma, suspicion of 
multifocal disease, and patients at high risk
Note.—ACR = American College of Radiology, AGO = Association of Gynecological Oncology, DCIS = ductal carcinoma in situ, EU-
SOBI = European Society of Breast Imaging, EUSOMA = European Society of Breast Cancer Specialists, NCCN = National Comprehen-
sive Cancer Network, NICE = National Institute for Health and Care Excellence.
Table 1: BI-RADS and Supplemental Descriptors for the Evaluation of Lesions at Breast MRI
Sequence and Description Descriptor Terms
T1 native
 Breast composition Fibroglandular tissue Almost entirely fatty; scattered;  
heterogeneous; extreme
T1 postcontrast (approximately 90 sec)/SUB
 Background signal Background parenchymal enhancement Minimal; mild; moderate; marked
 Lesion Lesion type Focus; mass; non-mass
  Mass
Shape Round; oval; irregular
Margin Circumscribed; irregular; spiculated
Internal enhancement pattern Homogeneous; heterogeneous; rim  
enhancement; dark internal septations
  Non-mass enhancement
Distribution Focal; linear; segmental; regional; multiple 
regions; diffuse
Internal enhancement pattern Homogeneous; heterogeneous; clumped; 
clustered ring
T1 dynamic
 Signal intensity vs time curve Initial enhancement (relative  
enhancement at 90 sec)
Slow, ,50%; medium, 50%–100%; fast, 
.100%
Delayed phase (relative enhancement  
compared with peak)
Persistent, .10% increase; plateau, –10%  
to +10%; washout, .10% decrease
Ultrafast
 Inflow curve Time to enhancement (sec) Early, ,10; intermediate, 10–15; late, .15
Maximum slope (%/sec) Slow, ,6.4; intermediate, 6.4–13.3; rapid, 
.13.3
T2
 Lesion T2 signal intensity Signal intensity High; intermediate, low
 Edema Presence Absent; perifocal; prepectoral; unilateral  
diffuse; bilateral diffuse
DWI
 Lesion diffusion level ADC (mm2/sec) Very low, ,0.9; low, 0.9–1.3; intermediate, 
1.3–1.7; high, 1.7–2.1; very high, . 2.1
Note.—ADC = apparent diffusion coefficient, BI-RADS = Breast Imaging Reporting and Data System, DWI = diffusion-weighted imaging, 
SUB = subtraction.
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that women scheduled to undergo mastectomy are in fact 
more likely to undergo breast MRI, which explains the 
higher odds ratio for undergoing mastectomy mentioned 
above. Overall, breast MRI reduces the rate of re-excisions 
from 13.4% to 8%, while changes to more extensive surgery 
(12.5%) are balanced by changes to less extensive surgery in 
a virtually equal proportion of patients (12.7%). Whether 
these results are specific to certain groups of women with 
breast cancer remains to be evaluated.
Detection of contralateral breast cancer.—Breast MRI de-
picts occult contralateral disease in 5.5%–9.3% of women 
with known unilateral breast cancer; 37%–48% of these find-
ings (2%–4%) are malignant (85,95). The detected cancers 
are small (,1 cm), and about one-third are DCIS. In essence, 
the detection of contralateral cancer is a form of high-risk 
screening, with a cancer yield that exceeds the yield in BRCA 
mutation carriers. To date, no factors, including breast den-
sity, are associated with the likelihood of detecting contralat-
eral cancer (96).
additional disease that impacts treatment is detected 
in 20% of patients. Therefore, findings that impact 
the planned surgical procedure should be confirmed 
at pathologic examination prior to treatment. In 
initial studies, conversion of breast-conserving sur-
gery (BCS) to mastectomy for benign lesions was 
reported (86), which should be prevented. The high 
frequency of incidental lesions makes the use of a 
multiparametric protocol very valuable, because it 
may allow the classification of lesions as certainly be-
nign and obviate biopsy. For indeterminate lesions, 
MRI-directed US allows for a US-guided biopsy in 
57.5% of lesions, albeit more often for mass lesions 
than for areas of NME (87). Lesions that are occult 
at MRI-directed US remain suspicious and should 
be sampled with MRI-guided biopsy.
Using MRI findings in surgery.—Despite more 
accurate staging with MRI, this information has 
not translated into improved surgical outcomes. 
Study results show that women undergoing MRI 
have a higher likelihood of undergoing mastec-
tomy; an odds ratio of 1.39 was reported in the 
latest meta-analysis (88). However, incorporating 
the MRI information to reduce the re-excision 
rates in women treated with BCS is challenging. 
In the Comparative Effectiveness of MRI in Breast 
Cancer, or COMICE, trial (89), a nationwide 
British prospective randomized controlled study, 
surgeons did not use the better staging informa-
tion from preoperative MRI, leading to a virtu-
ally identical re-excision rate of 19% in both arms. 
Moreover, additional lesions led to mastectomy be-
cause they were presumed to be malignant because 
MRI-guided biopsy was not commonly available. 
However, a Swedish trial (90) showed an overall 
reduction in re-excision rates, from 15% to 5%. 
These two articles illustrate the importance of MRI guidance 
of surgery. MRI-guided localization, or MRI-guided bracket-
ing of the extent of a larger tumor or DCIS, helps surgeons use 
the information MRI offers (91). For lobular cancers, evidence 
clearly points to a reduction in the rate of re-excisions without 
increasing the rate of mastectomies (91–93).
These differences likely reflect the experience of breast 
surgeons with breast MRI and whether these findings are 
discussed in the multidisciplinary team. Also, the use of 
modern oncoplastic surgical techniques may affect the value 
of MRI. Unfortunately, these factors are not incorporated 
in any of the meta-analysis available, and because the larg-
est trials failed to account for experience, available meta-
analytic data are unreliable. The Preoperative Breast MRI 
in Clinical Practice: Multicenter International Prospective 
Meta-Analysis of Individual Data, or MIPA, trial is de-
signed to overcome these issues by prospectively monitor-
ing the effect of preoperative breast MRI in expert centers. 
Preliminary data in 2425 patients were reported at the Eu-
ropean Congress of Radiology in 2018 (94). Results showed 
Figure 5: Sagittal images from breast MRI in a 36-year-old woman with an 
invasive ductal carcinoma. (a) Image from pre-chemotherapy contrast-enhanced 
T1-weighted MRI shows a round, rim-enhancing mass. (b) Subtraction image on 
which the maximal diameter of the mass was measured up to 5.4 cm. (c) On image 
obtained after completion of six cycles of chemotherapy, the mass is not seen, and 
there is no residual enhancement on (d) the subtraction image (arrow). Surgical his-
topathologic examination revealed no residual invasive or in situ cancer, indicating 
pathologic complete response.
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sensitivities between 75.2% and 100% and specificities between 
83% and 98.4% are reported (108,109). The cancer detec-
tion rate among known BRCA1/2 carriers was 26.2 per 1000, 
compared with 5.4 per 1000 in high-risk non-mutation carriers 
(110). Annual screening MRI is also recommended in women 
who underwent chest irradiation before the age of 30 years, usu-
ally for treatment of lymphoma. Study results demonstrated 
higher sensitivity of both mammography and MRI—from 94% 
to 100%, with additional cancer detection rates of 4.1% using 
combined MRI and mammography (111,112). Of note, recent 
studies show virtually no incremental cancer detection rate of 
mammography in all high-risk individuals younger than age 40 
years, if screening MRI is also performed (113,114). Also, the 
cancers detected with MRI are both invasive carcinomas and 
DCIS, while the cancers detected solely with mammography 
are mainly DCIS. This is clinically significant because women at 
Long-term outcome effects of preoperative 
MRI.—To our knowledge, only a few studies have ex-
amined the long-term outcome effects of preoperative 
MRI. Most studies do not show a reduction in meta-
chronous second breast cancers (97,98), although 
one study showed a significant reduction in the oc-
currence of metachronous contralateral breast cancer 
(99). There is no evidence for improved disease-free or 
overall survival owing to preoperative MRI, although 
there is evidence that early detection of second can-
cers improves relative overall survival (100,101), 
particularly in younger women (102). However, 
these studies are mostly based on early reports that 
did not show a surgical benefit of MRI. These initial 
studies did not incorporate the MRI data (eg, MRI-
guided biopsies were not performed for suspicious 
findings). More recent but underpowered studies 
have shown nonsignificant reductions of ipsilateral 
tumor recurrence in women undergoing preopera-
tive MRI (103,104). In women who undergo breast- 
conserving treatment without radiation therapy, pre-
operative MRI improves breast cancer survival (odds 
ratio, 0.57) (98).
Screening Breast MRI
In high-risk populations, MRI is recommended as 
a supplemental screening examination by multiple 
national and international guidelines (105–107). 
This consensus is based on multiple studies that 
showed that MRI identified earlier stage disease than 
mammography and that combined MRI and mam-
mography is associated with improved survival rates 
(108,109). One should note that the literature on 
screening MRI is focused on high-risk women, in 
whom there is a higher prevalence of breast cancer 
and the sensitivity of mammography is lower. The 
widely adopted American Cancer Society guide-
lines stratified three categories of risk, on the basis 
of literature and/or expert consensus, to identify 
those women who may benefit from annual screen-
ing breast MRI (105). The risk factors include vari-
ous germline mutations, family history, and personal risk factors. 
Women may undergo genetic testing to determine if they carry 
these deleterious mutations, and there are various risk prediction 
models to determine their lifetime risk. The Tyrer-Cuzick (Inter-
national Breast Cancer Intervention Study, or IBIS) model is con-
sidered to be the most comprehensive model and is often used to 
determine whether breast MRI should be performed.
High-risk women.—The American Cancer Society and the 
American College of Radiology categorize women with a life-
time risk of more than 20% as high risk and recommend an-
nual screening MRI and mammography in this subset of women 
(105,106). This high-risk group includes many genetic muta-
tions (eg, BRCA1, BRCA2, PALPB2, TP53, PTEN, CHECK2, 
CDH1, ATM, and STK11). Most of the literature in the setting 
of high-risk screening focuses on BRCA1/2 carriers, for whom 
Figure 6: Sagittal images from breast MRI in a 69-year-old woman with an invasive 
ductal carcinoma of the triple-negative subtype. (a) Image from pre-chemotherapy 
contrast-enhanced T1-weighted MRI shows a round, enhancing mass. The maximal 
diameter of the mass was measured as 3.3 cm. (b) Image from pre-chemotherapy 
T2-weighted MRI shows a round mass with peritumoral edema (arrow). (c) On image 
obtained after the completion of six cycles of chemotherapy, the mass shows a con-
centric shrinkage pattern. The maximal diameter of the residual mass was measured 
as 1.4 cm in the early postcontrast phase, and [(3.3 2 1.4)/3.3] · 100% = 58% 
reduction in the initial tumor diameter. It is suggestive of partial response. (d) Image 
from post-chemotherapy T2-weighted MRI shows an indistinct mass with disappeared 
peritumoral edema (arrow). Surgical histopathologic examination revealed a 1.5-cm 
invasive ductal carcinoma.
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The study demonstrates that there is a potentially larger 
number of women who may benefit from a screening breast 
MRI examination. It also highlights a strength of MRI: the 
low false-negative rates, as demonstrated by the low number of 
interval cancers (120,121). Also, because of improved spatial 
and temporal resolution and increased experience among ra-
diologists, the number of false-positive findings has decreased. 
Lee et al (122) recently showed that community practices in 
the Breast Cancer Surveillance Consortium met and/or ap-
proached the American College of Radiology BI-RADS per-
formance benchmarks for screening MRI.
Abbreviated MRI.—High costs and a limited availability of 
MRI units are the main factors that preclude the widespread 
use of screening MRI. Abbreviated MRI, with shorter image ac-
quisition and interpretation times, may increase the availability 
of breast MRI and reduce the costs. Kuhl et al (23) introduced 
the concept of an abbreviated protocol that consisted of one 
pre- and one postcontrast T1-weighted acquisition and found 
equivalent diagnostic accuracy for the abbreviated and full pro-
tocols among 443 women and 606 MRI studies. A recent re-
view of 21 studies (24) on abbreviated breast MRI performed 
in eight countries and in more than 4500 women confirmed 
the diagnostic accuracy was similar to the full MRI protocol. 
These studies evaluated a variety of abbreviated protocols. Also, 
ultrafast sequences may be used to obtain dynamic information 
without lengthening the protocol, maintaining a high diagnostic 
accuracy (123). Although breast MRI without intravenous con-
trast material administration would be useful for screening, the 
current techniques, particularly DWI, are not sensitive enough 
to replace contrast-enhanced breast MRI (124,125).
Overall, it is important to offer breast MRI to those women 
who benefit most. Risk prediction models may incorporate ad-
ditional imaging biomarkers, such as mammographic density 
and background parenchymal enhancement at MRI (126,127). 
Single nucleotide polymorphisms (SNPs) in saliva specimens are 
increased risk, particularly BRCA1 mutation carriers, are suscep-
tible to the effects of radiation, and there is increasing evidence 
to reconsider the role of mammography if a concurrent breast 
MRI examination is also being performed (115,116).
Intermediate-risk women.—The American Cancer Society 
guidelines consider women to be at an intermediate risk of breast 
cancer if they have a lifetime risk of between 15% and 20%, a per-
sonal history of breast cancer, dense breasts at mammography, or 
a history of high-risk lesions at biopsy (specifically, atypical ductal 
hyperplasia, atypical lobular hyperplasia, and lobular carcinoma 
in situ) (105). These guidelines, published in 2007, concluded 
that there was insufficient evidence to recommend for or against 
screening. However, multiple studies have since been published 
that support the role of MRI, especially among women with a 
personal history of breast cancer. In this setting, the sensitivity 
of mammography for early detection of second breast cancers is 
lower because of overlying postoperative changes. Studies in pa-
tients with personal histories of breast cancer show a consistently 
high cancer detection rate with MRI, ranging from 10 to 29 can-
cers per 1000 (117,118). In fact, MRI performed better in this 
subset of women than in patients with genetic or family histories, 
with fewer false-positive findings, higher specificity, and equiva-
lent sensitivity and cancer detection rates (118). As a result, the 
American College of Radiology now recommends annual breast 
MRI for women with dense breasts and a previous breast cancer 
diagnosis at an age younger than 50 years (106).
Although the American Cancer Society recommends against 
screening breast MRI in women at average risk (lifetime risk , 
15%), Kuhl et al (119) reported detection of 22.6 additional 
cancers per 1000 screening examinations in women with nega-
tive mammography and US examinations in a prevalent round 
(105). In subsequent incident rounds, the cancer detection rate 
with MRI was 6.9 per 1000. Hence, the decision to recommend 
screening MRI only in high-risk women in whom there is a 
higher prevalence of breast cancer may need to be revisited.
Table 3: Evaluation of Target and Non-Target Lesions according to RECIST, Version 1.1
Type of Lesion and Pathologic Response Criteria
Target lesions
 Complete response (CR) Disappearance of all target lesions. Any pathologic lymph nodes (when target or non-target) 
must have reduction in short axis to , 10 mm
 Partial response (PR) At least a 30% decrease in the sum of diameters of target lesions, taking as reference the base-
line sum diameters
 Progressive disease (PD) At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest 
sum on study (this includes the baseline sum if that is the smallest on study). In addition to 
the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 
mm. (Note: The appearance of one or more new lesions is also considered progression)
 Stable disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as 
reference the smallest sum diameters while on study
Non-target lesions
 Complete response (CR) Disappearance of all non-target lesions. All lymph nodes , 10 mm in short axis
 Non-CR/non-PD Persistence of one or more nontarget lesion(s)
 Progressive disease (PD) Unequivocal progression of existing nontarget lesions. Appearance of one or more new lesions
Note.—RECIST = Response Evaluation Criteria in Solid Tumors.
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than other prognostic indicators, such as tumor diameter change 
(135). Furthermore, volume change showed the strongest predic-
tive performance for pCR after the first cycle of chemotherapy. 
Modification of an ineffective chemotherapeutic regimen at an 
early time point when MRI indicates absence of response is im-
portant to avoid the unnecessary toxicity of chemotherapeutic 
agents but is currently mostly restricted to adaptive clinical trials. 
Changes in time–signal intensity curve analysis or pharmacoki-
netic modeling are also associated with response to NAC, with an 
early decrease in enhancement as an important predictor of even-
tual response (136,137). Likewise, an increase in ADC is predic-
tive of response (138,139), with a reported sensitivity and specific-
ity of 88% and 79% for the prediction of pCR (139). However, 
promising genetic markers that may also improve 
risk prediction models (128). Personalized screen-
ing, with the assessment of multiple risk factors and 
the use of “big data” analytics, is being proposed as 
new paradigm to allow for more nuanced stratifica-
tion of breast cancer risk.
Evaluation of Women Treated with 
Neoadjuvant Chemotherapy
One of the major benefits of neoadjuvant chemo-
therapy (NAC) is achieving pathologic complete 
response (pCR) in women with human epidermal 
growth factor receptor 2 (HER2)-enriched cancer, 
triple-negative cancer, and many luminal-B cancers. 
Also, NAC may decrease the size of locally advanced 
breast tumors, increasing the chance for BCS, and 
result in downstaging of the axilla, possibly avoiding 
axillary lymph node dissection. Although achiev-
ing pCR is a favorable prognostic factor, survival 
outcomes of patients treated with preoperative che-
motherapy are similar to those of patients treated 
with adjuvant chemotherapy (129,130). To evaluate 
residual tumor size, physical examination, mam-
mography, US, and MRI have been used. Of these, 
MRI is the most accurate method, as it is difficult for 
other modalities to distinguish posttreatment fibrosis 
or postbiopsy change from residual tumor following 
NAC (131,132). However, because findings of breast 
cancers following NAC vary depending on tumor 
subtype, histologic type, and time points of MRI 
acquisitions, a refined strategy for accurate interpre-
tation is crucial. The purpose of the MRI examina-
tion should also be understood. From an oncologist’s 
perspective, assessing response to a specific regimen 
and measuring changes in invasive tumor size is im-
portant. Residual DCIS might not be the oncolo-
gist’s concern. For a surgeon, to achieve a negative 
margin during BCS, tumor extent, including DCIS, 
should be measured. Thus, separate strategies might 
be needed to determine response to a specific che-
motherapy regimen and to determine residual tumor 
size after NAC.
Tumor response assessment during chemother-
apy.—To assess response to chemotherapy, changes in maxi-
mum tumor size, tumor volume, and enhancement kinetics 
at imaging have been investigated (133), and functional tech-
niques, including various DWI approaches and molecular im-
aging techniques, are being investigated. The Response Evalua-
tion Criteria in Solid Tumors. or RECIST, are the most widely 
used standardized criteria for response assessment (134). Four 
categories of response—complete response (Fig 5), partial re-
sponse (Fig 6), stable disease, and progressive disease—are rec-
ognized (Table 3).
Semiautomated volumetric measurements are available with 
three-dimensional software for MRI (Fig 7). Tumor volume 
changes have a stronger association with recurrence-free survival 
Figure 7: Sagittal images from breast MRI in a 31-year-old woman with an inva-
sive ductal carcinoma. (a) Pre-chemotherapy maximal intensity projection (MIP) im-
age from contrast-enhanced MRI shows a 4.9-cm round mass. (b) Post-chemotherapy 
MIP image from contrast-enhanced MRI shows a 1.7-cm irregular mass, and [(4.9 2 
1.7)/4.9] · 100% = 65% reduction of the initial tumor diameter. It is suggestive of 
partial response. (c, d) Computer-aided volumetry images show 94% volume reduc-
tion, from (c) 26.5 cm3 to (d) 1.6 cm3.
Mann et al
Radiology: Volume 292: Number 3—September 2019  n  radiology.rsna.org 531
the invasive component, as well as determination of pCR, is 
more accurate with the standard postcontrast series (Fig 10, 
Table 4). These results can be explained by the finding that 
enhancement of residual DCIS after NAC tends to be delayed 
as a result of the antiangiogenic effect of chemotherapy (148). 
Consequently, for this indication, inflow dynamics cannot 
completely replace late phase information.
Presurgical assessment for prediction of pCR.—With the 
advent of targeted therapy, the rates of pCR have been mark-
edly increased, up to 50%–60%, especially for HER2-positive 
and triple-negative breast cancers (149). Consequently, there is 
a growing interest to evaluate whether the omission of surgery 
might be feasible in patients in whom imaging findings indicate 
to implement volumetric or functional assessment 
as alternatives to conventional size measurements, 
standardization of image acquisition, wide availabil-
ity of postprocessing software, and further studies are 
needed.
Presurgical assessment after NAC to assess the 
potential of BCS.—BCS following NAC is consid-
ered safe because no significant difference has been 
found in local recurrence rates between a BCS group 
and a mastectomy group or between a downstaged 
BCS group and a preplanned BCS group (140,141). 
An age of younger than 40 years is associated with 
a higher rate of local recurrence (142). MRI can 
guide BCS following NAC, although it has not been 
proven that preoperative MRI is associated with im-
proved surgical outcomes or recurrence rates (143).
For the detection of residual cancer after NAC, a 
meta-analysis including 44 studies (131) found that 
the median sensitivity was 92% and the median 
specificity was 90%. Although MRI has a better 
correlation with pathologic tumor size after NAC 
than physical examination, mammography, or US 
(131,132), underestimation or overestimation can 
occur because of scattered microscopic foci of resid-
ual tumor or fibrosis (144). Tumor size evaluation 
after NAC is therefore somewhat less reliable than 
that before NAC.
Size estimations in triple-negative tumors or 
HER2-positive tumors have been shown to be 
more accurate compared with those in hormone 
receptor–positive/HER2-negative tumors in the 
evaluation of residual tumor and the prediction 
of pCR (144,145) (Fig 8). The size of lobular or 
hormone receptor–positive/HER2-negative tumors 
tends to be underestimated (146) (Fig 9). These 
results can be explained by the fact that hormone 
receptor–positive/HER2-negative tumors more fre-
quently manifest as diffuse NME and reduce into 
multiple small foci following chemotherapy (147). 
The presence of NME at preoperative MRI is also 
associated with worse local-regional recurrence-free 
survival in patients who underwent BCS after NAC 
(142), with recurrences usually manifesting in the same quad-
rant as the original tumor.
Triple-negative tumors more often manifest as unifocal 
or multifocal masses than as areas of NME and often show a 
shrinking reduction pattern after chemotherapy (147) (Fig 6). 
Therefore, tumor size measurement after NAC on MRI is more 
challenging for hormone receptor–positive/HER2-negative tu-
mors than for other tumor subtypes, and a tailored interpre-
tation strategy is needed that takes tumor subtype and MRI 
phenotype into account.
To better determine the surgical tumor size after NAC, it 
may be beneficial to evaluate delayed phase images (obtained 
6 minutes after contrast material administration), as these 
better show residual DCIS components (146). Evaluation of 
Figure 8: Images in 35-year-old woman with an invasive ductal carcinoma of the 
human epidermal growth factor receptor 2–positive/hormone receptor–negative 
tumor subtype. (a) Pre-chemotherapy mammogram in the mediolateral oblique view 
shows diffuse, multifocal masses with calcifications in the upper breast. (b) Image 
from pre-chemotherapy MRI (maximum intensity projection of early postcontrast 
series in the sagittal plane) shows multiple masses with areas of non-mass enhance-
ment (arrows) in the upper breast. Although (c) post-chemotherapy mammogram in 
the mediolateral oblique view shows residual regional calcifications, (d) image from 
post-chemotherapy MRI (maximum intensity projection of early postcontrast series in 
the sagittal plane) shows no enhancing lesion. Surgical histopathologic examination 
revealed a pathologic complete response. MRI was more accurate than mammogra-
phy in the evaluation of residual tumor extent after chemotherapy.
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survival increases (153). MRI depicts the primary cancer in 
the breast in up to 60% of cases and allows planning of ap-
propriate treatment. Importantly, when the MRI findings are 
that pCR is achieved (150,151). MRI has consistently shown 
high sensitivities (accurate identification of residual cancer) of 
83%–92% and intermediate specificities (accurate identifica-
tion of pCR) of 47%–63% in the prediction of 
pCR (131,132). Absence of enhancement in the 
tumor bed at visual assessment is the most com-
monly used imaging criterion for pCR. It has been 
reported that the absence of enhancement on im-
ages from delayed phase MRI increases the prob-
ability of pCR 28 times when compared with the 
presence of residual enhancement (148). Current 
trials selecting patients for percutaneous biopsy 
to omit surgery generally use absence of residual 
enhancement for patient selection. Preliminary re-
sults show that percutaneous biopsy increases the 
negative predictive value of MRI in the diagnosis 
of pCR from 76.7% to 94.4% (151), thus render-
ing this approach potentially feasible. However, 
chemotherapy-induced fibrosis, inflammation, or 
granulation tissue even without residual cancer 
might still lead to enhancement at the tumor site, 
mimicking residual cancer. Quantification of re-
sidual enhancement may yield a higher sensitivity 
for pCR at the cost of a reduction in specificity 
(152).
Other Indications for Breast MRI
Carcinoma of unknown primary origin.—In 
the scenario of an axillary carcinoma of unknown 
primary origin with suspicion of origin in the 
breast, treatment of the affected breast is impor-
tant because local recurrence decreases and overall 
Figure 9: Images from contrast-enhanced breast MRI in a 48-year-old woman with 
an invasive ductal carcinoma of the hormone receptor–positive/human epidermal 
growth factor receptor 2–negative subtype. (a) Image from pre-chemotherapy MRI 
shows multiple, irregular areas of non-mass enhancement (NME) (arrows) in the 
upper and lower breast. (b) On image obtained after completion of six cycles of 
chemotherapy, the areas of NME have decreased in size. The residual tumor in the 
upper breast was measured as 5.3 cm (arrow). The lower area of NME was con-
sidered to have resolved. However, surgical histopathologic examination revealed 
a 12.1-cm invasive ductal carcinoma in the upper and lower breast. Residual tumor 
size was therefore strongly underestimated at post-chemotherapy MRI.
Figure 10: Images from contrast-enhanced breast MRI in a 46-year-old woman with an invasive ductal carcinoma of the 
human epidermal growth factor receptor 2–positive subtype. (a) Image from pre-chemotherapy MRI shows a 5.5-cm irregular 
enhancing mass in upper breast. (b) Image obtained after completion of six cycles of taxane and herceptin in the early phase 
(90 seconds) of postcontrast MRI shows an architectural distortion without a definite enhancing lesion in the upper breast (ar-
row). (c) On image obtained in the delayed phase (360 seconds) of postcontrast MRI, the enhancing lesion was measured as 
2.6 cm (arrow). Surgical histopathologic examination revealed a 0.5-cm invasive cancer and a 2.2-cm total tumor size (includ-
ing both invasive tumor and ductal carcinoma in situ).
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patient selection to neoadjuvant chemotherapy and is the mo-
dality of choice for modification of therapeutic agents, for pre-
surgical assessment of residual tumor size to determine breast-
conserving surgery candidacy, and for prediction of pathologic 
complete response to triage patients to clinical trials omitting 
surgery. From an economic perspective, and to improve patient 
comfort, breast MRI can be optimized by adjusting the protocol 
with regard to the indication. For indications where the exclu-
sion of disease is most important, abbreviated protocols may be 
used. On the other hand, when lesions need to be characterized 
in detail, or when the frequency of findings is high, multipa-
rametric protocols are mandatory. Because therapy may reduce 
enhancement in breast lesions, during and after chemotherapy, 
evaluation of late phase enhancement may still be important.
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negative, radiation therapy to the ipsilateral breast is as safe as 
mastectomy, and therefore MRI in this setting may prevent 
unnecessary mastectomies (154,155).
Problem solving.—Problem solving relies on the high negative 
predictive value (NPV) of breast MRI. It is typically used for find-
ings that are not certainly benign but that cannot be sampled for 
biopsy by using conventional imaging guidance. The most com-
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Note.—HER2 = human epidermal growth factor receptor 2.
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